Henry Schein, Inc. (HSIC) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

BULLISH

Citigroup has initiated coverage on Henry Schein with a 'Buy' rating and set a price target of $100, signaling a new positive analyst view. This development suggests a belief in the company's future prospects, which could influence investor sentiment. However, BTIG has also initiated coverage with a 'Neutral' rating, indicating that current market conditions and company-specific factors are seen as largely balanced and priced into the stock. This creates a divergence in analyst sentiment, and investors will be watching for any shifts that could alter these initial stances. The market reaction to these differing views and any subsequent analyst commentary will be key. Traders should monitor for any news that could impact Henry Schein's valuation or market position to understand which analyst view might gain traction.

Market Data

HSIC Stock Snapshot

Henry Schein, Inc. · Healthcare · henryschein.com

Henry Schein, Inc. is a global distributor of healthcare products and services, primarily catering to dental and medical practitioners. The company's core business revolves around providing a comprehensive suite of offerings, including dental merchandise, equipment, and pharmaceuticals, along with related services. Henry Schein also offers a range of specialty products, such as dental implants and biomaterials, differentiating itself through its broad product portfolio. Furthermore, the company supports its customers with practice management software and educational resources, solidifying its position as a value-added partner within the healthcare sector. Established in 1932, Henry Schein serves a diverse customer base, including private practices, laboratories, and institutional healthcare providers.

HSIC is currently trading at $78.75, giving Henry Schein, Inc. a market cap of 9.04B and a P/E ratio of 22.7. Today's range spans $78.03–$79.96, with shares opening at $78.04 and moving down $0.09 (0.1%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 79/100.

Over the past year HSIC has traded between $61.95 and $89.29 - the current price is +27.1% off the 52-week low and -11.8% from the high. 23 analysts cover the stock with a Buy consensus and a mean 12-month target of $90.00 (range $61.00–$104.00), implying upside of +14.3%.

HSIC is a small-cap Healthcare name (9.04B market cap) with a BUY technical read (82/100) and bullish sentiment (79/100). Price: $78.75 (in the middle of its 52-week range). (P/E: 22.7) The 52-week window of $61.95–$89.29 shows the full range this stock can trade - and at this cap tier, once momentum builds, the move from in the middle of its 52-week range to either extreme tends to happen faster than the timeline in larger-cap names.

HSIC|EarningsHenry Schein, Inc.

Earnings Summary

Henry Schein, Inc. is a global distributor of healthcare products and services, primarily serving dental and medical practitioners with a comprehensive suite of offerings including merchandise, equipment, pharmaceuticals, and practice management software. Operating within the Healthcare sector's Medical Distribution industry, the company has established itself as a value-added partner since its founding in 1932. In its most recent reported quarters, Henry Schein demonstrated a mixed performance. For Q3 2025, the company reported actual EPS of $1.38, exceeding the estimate of $1.27912, and revenue of $3.339 billion. This followed a Q2 2025 where actual EPS was $1.10 against an estimate of $1.19055, with revenue at $3.240 billion. Prior to this, Q1 2025 saw actual EPS of $1.15 beating the estimate of $1.11013, and Q4 2024 reported actual EPS of $1.19 against an estimate of $1.20888. This pattern indicates an acceleration in EPS beats in the latter half of the reported period, with revenue figures generally showing an upward trend. Historically, Henry Schein has shown a trajectory of revenue growth, though EPS performance against analyst estimates has varied. The company beat estimates in Q1 2025 and Q3 2025, and Q4 2025, but missed in Q2 2025 and Q4 2024, suggesting an inconsistent beat/miss pattern in EPS relative to expectations. Recent news highlights a divergence in analyst sentiment, with Citigroup initiating coverage with a 'Buy' rating and a $100 price target, while BTIG initiated with a 'Neutral' rating. This mixed analyst view, alongside identified risk factors, creates a dynamic environment for investors. Moving forward, investors will be watching for continued execution on growth initiatives and how the company addresses the identified risk factors, particularly in light of the differing analyst outlooks.

Earnings | EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$1.22	-	-
Q4'25	$1.26	$1.34	+6.3%
Q3'25	$1.28	$1.38	+7.9%
Q2'25	$1.19	$1.10	-7.6%
Q1'25	$1.11	$1.15	+3.6%
Q4'24	$1.21	$1.19	-1.6%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$3.3B	-	-
Q4'25	$3.3B	$3.4B	+3.1%
Q3'25	-	$3.3B	-
Q2'25	-	$3.2B	-
Q1'25	-	$3.2B	-
Q4'24	-	$3.2B	-

Technical Score (1D)

BUY

News Sentiment

BULLISH

Market Data

HSIC Stock Snapshot

Henry Schein, Inc. · Healthcare · henryschein.com

News Sentiment Analysis

Sentiment gathered from recent headlines

79/100

Strong NegativeNeutralStrong Positive

BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

Henry Schein (HSIC) demonstrates a strong track record of exceeding earnings expectations. The company's current positioning suggests a high probability of another earnings beat in its upcoming report. This trend indicates robust operational performance and effective market strategies.

What did this article say?

Henry Schein (HSIC) is identified as a strong value stock, driven by favorable metrics that suggest undervaluation. The analysis highlights key financial indicators supporting this assessment, implying potential upside for investors. This perspective suggests that the market may not be fully pricing in the company's underlying worth.

What did this article say?

BTIG has initiated coverage of Henry Schein (HSIC) with a Neutral rating, reflecting a balanced view of the company's prospects. The firm's assessment suggests that current market conditions and company-specific factors are largely priced into the stock. Investors will be watching for any shifts in market dynamics or company performance that could alter this initial neutral stance.

What did this article say?

BTIG has initiated coverage on Henry Schein (HSIC) with a Neutral rating. The analyst's assessment suggests a balanced view of the company's current standing. This initiation provides a baseline perspective from a new research provider.

What did this article say?

Citigroup has initiated coverage on Henry Schein (HSIC) with a 'Buy' rating, establishing a price target of $100. This analyst action signals a positive outlook on the company's prospects. Traders should monitor market reaction and any subsequent analyst commentary.

What did this article say?

Citigroup has initiated coverage on Henry Schein (HSIC) with a "Buy" rating and set a price target of $100. This analyst initiation suggests a positive outlook on the company's prospects. The current average rating among analysts is "Overweight" with a mean price target of $89.23.

What did this article say?

Argus Research has raised its price target for Henry Schein (HSIC) to $85.00, maintaining a 'BUY' investment rating. The firm's assessment highlights high ratings in Industry, Safety, and Value, with medium ratings in Management, Financial Strength, and Growth. This upward revision suggests increasing confidence in HSIC's fundamentals and market position.

What did this article say?

Henry Schein (HSIC) is highlighted as a compelling long-term growth stock, suggesting positive fundamental momentum. The article likely details factors contributing to its sustained outperformance and potential for future appreciation. Investors should monitor continued execution on growth initiatives and market share gains.

What did this article say?

An analysis identifies three key risks associated with Henry Schein (HSIC), suggesting potential downsides for investors. The article contrasts these risks by recommending an alternative stock for consideration. Investors should monitor the specific risk factors detailed for HSIC.

What did this article say?

Henry Schein is slated to release its first-quarter financial results soon. Current analyst consensus forecasts a modest single-digit percentage rise in earnings per share for the period. This upcoming report will provide key insights into the company's operational performance and near-term outlook.

HSIC|EarningsHenry Schein, Inc.

Earnings Summary

Earnings | EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$1.22	-	-
Q4'25	$1.26	$1.34	+6.3%
Q3'25	$1.28	$1.38	+7.9%
Q2'25	$1.19	$1.10	-7.6%
Q1'25	$1.11	$1.15	+3.6%
Q4'24	$1.21	$1.19	-1.6%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q1'26	$3.3B	-	-
Q4'25	$3.3B	$3.4B	+3.1%
Q3'25	-	$3.3B	-
Q2'25	-	$3.2B	-
Q1'25	-	$3.2B	-
Q4'24	-	$3.2B	-

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles

What did this article say?

HSIC·Henry Schein, Inc.

HSIC Stock Snapshot

Earnings | EPS

Revenue

HSIC·Henry Schein, Inc.

HSIC Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Earnings | EPS

Revenue

News Sentiment Analysis

Recent News Coverage

HSIC·Henry Schein, Inc.

HSIC Stock Snapshot

Earnings | EPS

Revenue

HSIC·Henry Schein, Inc.

HSIC Stock Snapshot

News Sentiment Analysis

Recent News Coverage

Earnings | EPS

Revenue

Discover More

News Sentiment Analysis

Recent News Coverage

Discover More